These results establish Fyn kinase as a critical connection between Aβ and Tau pathology, with dual therapeutic implications, including both targeting upstream (Aβ‐Fyn interaction) and downstream (Fyn‐Tau signaling) for both AD and primary tauopathies [203, 204]. The gene discussed is MAPT; the disease is tauopathy.